106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2022 All rights reserved
ASCORCC04222a
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve
cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/genitourinary-cancer-guidelines.
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
genitourinary-cancer-guidelines. Copyright © 2022 by American Society of Clinical Oncolog y.
All rights reserved.
Source
Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al. Management of Metastatic Clear
Cell Renal Cell Carcinoma: ASCO Guideline. J Clin Oncol. 2022 June 21.
doi:10.1200/JCO.22.00868.
Abbreviations
CAIX, carbonic anhydrase IX; ccRCC, clear cell renal cell carcinoma; HD-IL2, high dose
interleukin-2; IMDC, International Metastatic RCC Database Consortium; PAX8, paired
box gene 8; RANKL, receptor activator of nuclear factor kappa-Β ligand; RECIST,
response evaluation criteria in solid tumors; TKI, tyrosine kinase inhibitor; VEGFR,
vascular endothelial growth factor receptor
